Biotech Oncorus to offer 5.8 million shares in planned IPO, priced at $14 to $16 each

/ / News

Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each. The company has applied to list on Nasdaq, under the ticker “ONKR.” Jefferies, Evercore ISI and Piper Sandler are underwriting the deal with proceeds earmarked for clinical trials, to expand manufacturing capabilities and for working capital. “We are a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients,” the company saysin its prospectus.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.